Treg: Regulatory T Cells and T Helper Cells

Valbonne, France, November 26, 2012 -­ TxCell SA, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, announces today that it raised €12.4 million in a third financing round. This additional capital was provided by the InnoBio fund, managed by CDC Entreprises, for €6 million and by TxCell's existing shareholders Auriga Partners and Seventure Partners.

Valbonne, France, October 24, 2012 -­ TxCell SA, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, announces today the publication of the complete results of CATS1 Crohn's disease study in Gastroenterology, the most prominent journal in the field of gastrointestinal disease, and the presentation of the long term treatment extension data at UEGW, the main European gastroenterology meeting.

Valbonne, France, February 21, 2012 -­ TxCell SA, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, announces today immuno-monitoring results of the phase I/II study in Crohnʼs disease (CATS1) with its leading product candidate Ovasave®. The results of this study, performed on 20 patients, were presented at the 7th European Crohnʼs and Colitis Organization meeting, in Barcelona, held February 16 -18.

Valbonne, France, October 25, 2011 - TxCell SA, a biotechnology company developing Treg cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical needs, announces today the presentation of final positive results of the phase I/II study in Crohn’s disease (CATS-1) with its leading product candidate, OvaSave®. The results of this study, performed on 20 patients, were announced at the United European Gastroenterology Week (UEGW) in Stockholm, held Oct 22 to 26.

Valbonne, France, June 1, 2011 - TxCell SA, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, announces today the treatment of the first patient in the long term maintenance phase of CATS1 study. This CATS1 study extension was recently approved by AFSSAPS, the French regulatory agency, allowing the continuation of regular maintenance treatment for those patients that benefited from Ovasave, a type 1 regulatory T cell based immunotherapy, in the first part of the study.

Valbonne, France, March 9, 2011 - TxCell SA, a biotechnology company developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need, today announced the appointment of Dr. François Meyer as its chief executive officer.

June 2010 - TxCell announces the successful completion of the preclinical development of TX-RAD

Valbonne, France, June 15, 2010. – TxCell SA, a French biotechnology company developing autologous cell-based therapies using Type 1 T-regulatory lymphocytes (Tr1) for the treatment of chronic inflammatory and autoimmune diseases, today announced the successful completion of the preclinical development of its TX-RAD product for the treatment of inflammatory arthritis.

April 2010 - TxCell announces positive preliminary results from the PhI/IIa clinical trial of OvaSave

Valbonne, France, April 29, 2010. – TxCell SA, a French biotechnology company developing autologous cell-based therapies using Type 1 T-regulatory lymphocytes (Tr1) for the treatment of chronic inflammatory and autoimmune diseases, today announced positive preliminary results from the ongoing Phase I/IIa clinical trial regarding OvaSave, an investigational new drug, in patients with severe and refractory Crohn’s disease. Preliminary results from the study showed that OvaSave is well-tolerated and that an encouraging efficacy signal has been observed.

January 2010 - TxCell appoints Miguel Forte as Chief Medical Officer

Valbonne, France, January 25, 2010. – TxCell SA, a biotechnology company developing cell-based therapies using Type 1 T-regulatory lymphocytes for treating chronic inflammatory and autoimmune diseases, has appointed Miguel Forte as Chief Medical Officer (CMO).

September 2008 - TxCell appoints Marc D. Beer as Chairman of the Supervisory Board

Valbonne, France, September 10, 2008 - TxCell, a leading biotech company, today announced that its Board of Directors has appointed Marc D. Beer as Chairman of the firm's Supervisory Board. TxCell’s strategy is to develop a new class of autologous cellular immunotherapy products that are uniquely designed to regulate a patient's own immune system.

February 2008 - TxCell completes a 10.5 million second round and initiates its first clinical trial

Valbonne, France, February 28, 2008 – TxCell, a biopharmaceutical firm specialized in treatment for autoimmune and chronic inflammatory diseases, announces today a fundraising of €10.5 million, after its second round of fundraising. In 2007 the company received from the AFSSAPS (French Health Products Safety Agency) the authorization to start its first clinical test of cell therapy based on Tr1 Lymphocyte in Crohn disease.